Ajay Royan Buys Shares of Fractyl Health

Ajay Royan, a notable insider, increased his stake in Fractyl Health, Inc. (NasdaqGM: GUTS) by purchasing 23,000 shares on June 12, 2026. The shares were bought at an average price of $0.85 each, totaling a value of $19,550. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Fractyl Health, Inc.

Several insiders have been active in acquiring shares of Fractyl Health recently. Ajay Royan made another purchase on June 10, 2026, buying 22,500 shares. On the same day, Kelly Ann Barnes and William Bradley each bought 22,500 shares, while Christopher Charles Thompson also acquired 22,500 shares. Bradley made an additional purchase of 68,493 shares at $0.73 per share.

Other Institutional Activity in Fractyl Health

Institutional investors have shown varied interest in Fractyl Health. Nantahala Capital Management, LLC increased its holdings by 2,518,079 shares, bringing its total to 13,364,519 shares valued at approximately $6.12 million. 683 Capital Management, LLC added 679,615 shares, reaching 6,727,235 shares worth about $3.08 million. Pale Fire Capital SE significantly boosted its stake by 2,711,103 shares, totaling 5,921,045 shares valued at $2.71 million. Vanguard Capital Management LLC now holds 5,533,006 shares, and General Catalyst Group Management, LLC maintains its position with 4,884,193 shares.

Fractyl Health Stock Snapshot

Shares of Fractyl Health (NasdaqGM: GUTS) traded near $0.83 recently. The company has a market capitalization of approximately $134.9 million. Fractyl Health is not currently profitable, which means it has no meaningful P/E ratio. The stock's beta is 2.34, indicating higher volatility compared to the market. Over the past year, the stock has ranged from $0.377 to $2.445. It has a 50-day moving average of $0.703 and a 200-day moving average of $1.097. The company's current ratio is 4.28, and its debt-to-equity ratio is 284.50.

Analysts Set New Price Targets

On June 4, 2026, HC Wainwright & Co. reiterated its buy rating for Fractyl Health, setting a price target of $8. Canaccord Genuity also maintained a buy rating with the same target. Morgan Stanley, however, downgraded the stock to a hold with a $2 target earlier in the year. Overall, the stock has a strong buy consensus from analysts, with a mean target price of $5.24 based on five opinions.

About Fractyl Health

Fractyl Health, Inc. is a biotechnology company based in Burlington, Massachusetts. It focuses on developing treatments for type 2 diabetes and obesity. The company's main product, the Revita DMR System, is a therapy designed to address duodenal dysfunction. Fractyl also works on Rejuva, a gene therapy platform aimed at providing long-term remission for metabolic diseases. Founded in 2010, the company is led by CEO Dr. Harith Rajagopalan.

Bottom Line

Ajay Royan's recent share purchase in Fractyl Health highlights continued insider interest in the company. As a metabolic therapeutics firm, Fractyl is working on innovative solutions for type 2 diabetes and obesity. Investors often track insider transactions for potential signals, but it's important to remember these filings are backward-looking and do not necessarily indicate current conditions.